Trump administration unveils Medicare negotiated price cuts for 15 drugs, including Ozempic

The Trump administration announced Medicare-negotiated 2027 prices for 15 drugs, projecting roughly $12 billion in Medicare savings versus last year and an estimated $685 million in beneficiary out-of-pocket relief, with the 2024 spend on these drugs at about $42.5 billion before rebates. Negotiated discounts range roughly 38%–85% off list prices — notable outcomes include Ozempic/Wegovy/Rybelsus cut to $274 (from $959) and Trelegy Ellipta to $175 (from $654) — and GLP-1s were taken in the round despite overlapping most-favored-nation agreements. The move tightens revenue exposure for affected drugmakers and could meaningfully affect earnings expectations for companies with large Medicare footprints, while raising policy and legal uncertainty about program interactions and industry responses.

Analysis

Market structure: Medicare’s negotiated cuts (e.g., Ozempic/Wegovy -71%, Ibrance -50%) transfer near-term cash flow from branded manufacturers to taxpayers and beneficiaries, directly pressuring revenue lines for GLP-1 specialists (Novo Nordisk) and selected oncology/inhaler franchises (Pfizer among others). Winners are Medicare, beneficiaries, and payers; losers are high-margin, Medicare-exposed product lines and firms with concentrated exposure. Expect pricing power erosion for drugs with large Part D share and increased incentive to chase commercial/cash customers.

Risk assessment: Tail risks include expansion of negotiation beyond Part D, adverse court rulings, or MFN interactions that further lower realized prices — each could remove 10–40% of US revenue for targeted drugs by 2027. Timeline: immediate equity volatility (days), guidance resets and analyst revisions (weeks–months), and realized P&L impact when prices take effect in 2027; hidden dependencies include opaque PBM rebates and MFN/tariff deals that can compress or offset net price changes. Key catalysts in next 30–120 days: CMS guidance on MFN interaction, company 2025 Q3/Q4 commentary, and any new litigation outcomes.

Trade implications: Tactical strategy is defined-risk bearish on NVO and defensive long on diversified large-cap pharma. Size aggressiveness to convictions: establish 1–2% portfolio short exposure to NVO via 12‑month put spreads (targeting ~30% downside), offset with 0.5–1% long PFE call spread exposure as a relative safety play. Rotate 3–5% away from GLP-1/concentrated diabetes exposure into healthcare services/PBM/insurers and large diversified pharmas; enter within 5 trading days and re-assess after CMS MFN clarification or Q3 earnings.

Contrarian angles: Consensus understates volume elasticity and international/commercial pricing levers — Novo can recapture margin via volume growth, formulary positioning, and non‑Medicare channels; historical parallels (insulin/statins) show negotiated prices often equalized by expanded volumes and assistance programs. The market could overshoot negative repricing for NVO — consider small, asymmetric long-call spreads (9–12 month) if shares fall >20% as a mean‑reversion hedge. Unintended consequences: firms may accelerate portfolio diversification away from Medicare-exposed assets, creating M&A and repurposing catalysts over 12–24 months.

Key Decisions for Investors

• Establish a 1–2% portfolio short on NVO via a defined-risk 12‑month put spread (buy 30% OTM put, sell 45% OTM put) within 5 trading days to express downside tied to Medicare pricing risk; trim if NVO falls >40% or if CMS issues clarifying guidance that limits price exposure.
• Establish a 0.75–1% long position in PFE via a 6–12 month call spread (buy 15% OTM, sell 35% OTM) as a defensive, diversified-pharma play; exit or re-weight on Q3/Q4 2025 results or if company guidance cuts materially (>5% EPS revision).
• Rotate 3–5% portfolio weight out of pure-play GLP-1/diabetes specialists into healthcare services/PBM and large diversified pharma over the next 30 days; prioritize names with >60% non-Medicare revenue exposure and stable margins.
• Buy a 0.5% notional 9–12 month long call spread on NVO (15% OTM strikes) as a contrarian asymmetric bet if shares drop >20% from pre-announcement levels, sizing to limit downside while capturing potential mean reversion if volume offsets price cuts.
• Monitor three specific catalysts in next 30–120 days: CMS MFN-Medicare interaction guidance (impact threshold >10% additional price reduction), district/circuit court rulings on IRA challenges (injunction risk), and company 2025 Q3 commentary on US payer mix and rebate strategies; close or adjust positions within 10 trading days of any of these events.